These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 18690593

  • 1. Single center experience with provisional abciximab therapy in complex lower limb interventions.
    Keo H, Diehm N, Baumgartner R, Husmann M, Baumgartner I.
    Vasa; 2008 Aug; 37(3):257-64. PubMed ID: 18690593
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Initial experience with the combination of reteplase and abciximab for thrombolytic therapy in peripheral arterial occlusive disease: a pilot study.
    Drescher P, Crain MR, Rilling WS.
    J Vasc Interv Radiol; 2002 Jan; 13(1):37-43. PubMed ID: 11788692
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Reteplase monotherapy and reteplase/abciximab combination therapy in peripheral arterial occlusive disease: results from the RELAX trial.
    Ouriel K, Castaneda F, McNamara T, Swischuk J, Tepe G, Smith JJ, Clark J, Duda S.
    J Vasc Interv Radiol; 2004 Mar; 15(3):229-38. PubMed ID: 15028807
    [Abstract] [Full Text] [Related]

  • 7. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.
    Merlini PA, Rossi M, Menozzi A, Buratti S, Brennan DM, Moliterno DJ, Topol EJ, Ardissino D.
    Circulation; 2004 May 11; 109(18):2203-6. PubMed ID: 15117843
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Hemorrhagic and vascular complications after percutaneous coronary intervention with adjunctive abciximab.
    Cote AV, Berger PB, Holmes DR, Scott CG, Bell MR.
    Mayo Clin Proc; 2001 Sep 11; 76(9):890-6. PubMed ID: 11560299
    [Abstract] [Full Text] [Related]

  • 10. Intracoronary abciximab use in patients undergoing PCI at a community hospital: a single operator experience.
    Patel SS, Rana H, Mascarenhas DA.
    J Cardiovasc Pharmacol Ther; 2008 Jun 11; 13(2):89-93. PubMed ID: 18413897
    [Abstract] [Full Text] [Related]

  • 11. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Mehran R, Stone GW, CADILLAC Investigators.
    Circulation; 2003 Sep 16; 108(11):1316-23. PubMed ID: 12939213
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Reteplase with or without abciximab for peripheral arterial occlusions: efficacy and adverse events.
    Hull JE, Hull MK, Urso JA.
    J Vasc Interv Radiol; 2004 Jun 16; 15(6):557-64. PubMed ID: 15178715
    [Abstract] [Full Text] [Related]

  • 14. Abciximab reduces monocyte tissue factor in carotid angioplasty and stenting.
    Kopp CW, Steiner S, Nasel C, Seidinger D, Mlekusch I, Lang W, Bartok A, Ahmadi R, Minar E.
    Stroke; 2003 Nov 16; 34(11):2560-7. PubMed ID: 14563968
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion after transradial coronary stenting.
    Bagur R, Bertrand OF, Rodés-Cabau J, Larose E, Rinfret S, Nguyen CM, Noel B, Larochellière RD, Poirier P, Costerousse O, Roy L.
    Catheter Cardiovasc Interv; 2009 Dec 01; 74(7):1010-6. PubMed ID: 19753635
    [Abstract] [Full Text] [Related]

  • 20. Aggressive therapy with intravenous abciximab and intra-arterial rtPA and additional PTA/stenting improves clinical outcome in acute vertebrobasilar occlusion: combined local fibrinolysis and intravenous abciximab in acute vertebrobasilar stroke treatment (FAST): results of a multicenter study.
    Eckert B, Koch C, Thomalla G, Kucinski T, Grzyska U, Roether J, Alfke K, Jansen O, Zeumer H.
    Stroke; 2005 Jun 01; 36(6):1160-5. PubMed ID: 15890988
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.